Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
License data |
|
Routes of administration |
Oral, IM, IV, Rectal |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic |
Biological half-life | 8–42 hours |
Excretion | Renal |
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
ECHA InfoCard | 100.000.300 |
Chemical and physical data | |
Formula | C11H18N2O3 |
Molar mass | 226.272 |
3D model (Jmol) | |
|
|
|
|
Amobarbital (formerly known as amylobarbitone or sodium amytal) is a drug that is a barbiturate derivative. It has sedative-hypnotic properties. It is a white crystalline powder with no odor and a slightly bitter taste. It was first synthesized in Germany in 1923. If amobarbital is taken for extended periods of time, physical and psychological dependence can develop. Amobarbital withdrawal mimics delirium tremens and may be life-threatening.
In an in vitro study in rat thalamic slices amobarbital worked by activating GABAA receptors, which decreased input resistance, depressed burst and tonic firing, especially in ventrobasal and intralaminar neurons, while at the same time increasing burst duration and mean conductance at individual chloride channels; this increased both the amplitude and decay time of postsynaptic currents.
Amobarbital has been used in a study to inhibit mitochondrial electron transport in the rat heart in an attempt to preserve mitochondrial function following reperfusion.
A 1988 study found that amobarbital increases benzodiazepine receptor binding in vivo with less potency than secobarbital and pentobarbital (in descending order), but greater than phenobarbital and barbital (in descending order). (Secobarbital > pentobarbital > amobarbital > phenobarbital > barbital)